# ‚öîÔ∏è ALS LONGITUDE PRIZE COLLABORATOR OUTREACH - MASTER ACTION PLAN ‚öîÔ∏è

**Date Created:** 2025-01-XX
**Status:** üîÑ **ACTIVE EXECUTION**
**Mission:** Secure 1+ collaborator acceptance for ALS Longitude Prize partnership
**Strategic Objective:** Pitch CrisPRO's **AI model architecture** (not just features), validated by AACR Abstract B025

---

## üéØ EXECUTIVE SUMMARY

### **The Mission**
Find and secure collaboration partners for the ALS Longitude Prize by demonstrating CrisPRO's unique AI model architecture (Evo2, SAE, S/P/E framework) with surgical precision email outreach.

### **Critical Success Criteria**
- ‚úÖ **1+ collaborator accepts partnership** (primary goal)
- ‚úÖ Email quality must meet "Alpha standard" (Mount Sinai depth for EVERY target)
- ‚úÖ Pitch AI model architecture, not just "features and functionalities"
- ‚úÖ Incorporate AACR Abstract B025 as validation proof point
- ‚úÖ Attach MOAT deck (3-page capability showcase)

### **What Went Wrong (Lessons Learned)**
- ‚ùå **"Half Ass" Email Quality:** Initial drafts for Ranks 6-13 were generic templates
- ‚úÖ **Fixed:** All emails rewritten to "Alpha standard" with deep research hooks
- üö® **Doctrine:** Never produce generic emails. Every target gets Mount Sinai-level depth.

---

## üìä COLLABORATOR RANKING & STATUS

### **TIER A: TOP PRIORITY (Ranks 1-5) - SURGICAL OUTREACH**

#### **RANK 1: SAGE BIONETWORKS** ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê
**Fit Score:** 4.8/5

**Why This Is THE Gateway:**
- **Direct access to ALS Knowledge Portal** (largest ALS dataset available)
- ARPA-H funded, Nature publications, trusted data leader
- Explicitly "Looking to partner" for biomarker discovery and drug repurposing
- Open science model aligns with our multimodal AI platform

**Key Contact:**
- LinkedIn: https://www.linkedin.com/company/sage-bionetworks/
- Platform: ALS Longitude Prize dashboard

**Email Strategy:**
- Lead with ARPA-H award and ALS Knowledge Portal stewardship
- Emphasize our "production-grade multimodal AI platform" for biomarker identification
- Position as computational layer unlocking insights from their data goldmine
- Reference AACR Abstract B025 as validation of our AI architecture

**Action Item:**
- [ ] Draft final email with AACR validation
- [ ] Attach MOAT deck
- [ ] Send as FIRST outreach (highest priority)

---

#### **RANK 2: BETH ISRAEL DEACONESS / DR. FENG TIAN LAB** ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê
**Fit Score:** 4.6/5

**Why Perfect Technical Match:**
- Combines ML algorithms + CRISPR tools (exactly our stack)
- Harvard Medical School faculty, $4M+ recent funding
- Focus: Computational dissection of genetic programs in ALS motor neurons
- Explicitly seeking AI/ML collaborators

**Key Contact:**
- **Name:** Dr. Feng Tian, PhD (Assistant Professor of Neurology)
- **Email:** ftianmcb@gmail.com
- **LinkedIn:** https://www.linkedin.com/in/feng-tian-87a7a1ab/
- **Lab:** https://research.bidmc.edu/feng-tian/

**Recent Work:**
- [2025-03] ALS Association grant for integrated stress response + neuroinflammation inhibition
- Hop on a Cure: $4M donation to Dr. Tian's lab for motor neuron rescue research

**Email Strategy:**
- Highlight integration of ML + CRISPR (our exact approach)
- Emphasize synthetic lethality predictions complementing his experimental screens
- Reference ALS Association funding as synergy point
- Position our platform as computational layer accelerating his target identification pipeline

**Action Item:**
- [ ] Draft final email with AACR validation
- [ ] Attach MOAT deck
- [ ] Send as SECOND outreach (high priority)

---

#### **RANK 3: YALE UNIVERSITY** ‚≠ê‚≠ê‚≠ê‚≠ê¬Ω
**Fit Score:** 4.4/5

**Why Breakthrough Research:**
- [2024-05] Discovered NLK as novel therapeutic target for ALS
- TDP-43 reduction ‚Üí improved motor function, extended survival in mouse models
- TDP-43 present in ALL ALS cases (broad applicability)
- Ivy League credibility + explicit collaboration interest

**Key Contact:**
- Requires follow-up research to identify specific PI
- Platform: ALS Longitude Prize dashboard (profile lacks specific contact)

**Recent Work:**
- NLK discovery reducing toxic TDP-43 (Nature-level breakthrough)
- Dr. Arthur Horwich's lab: Fast-firing motor neurons first to be lost in SOD1-linked ALS
- Active ALS Program with comprehensive clinical evaluation

**Email Strategy:**
- Lead with NLK discovery fascination (survival extension demonstrated)
- Position our AI platform for identifying complementary targets beyond NLK
- Emphasize synthetic lethal interactions and combination therapy predictions
- Reference TDP-43 ubiquity as validation of broad-applicability approach

**Action Item:**
- [ ] **BLOCKER:** Identify specific PI/contact (requires additional research)
- [ ] Draft email once contact identified
- [ ] Send as THIRD outreach (after contact resolution)

---

#### **RANK 4: BRIGHAM AND WOMEN'S / HARVARD MEDICAL SCHOOL** ‚≠ê‚≠ê‚≠ê‚≠ê
**Fit Score:** 4.3/5

**Why Clinical Depth:**
- Ann Romney Center specifically dedicated to ALS research
- First to discover monocyte changes as ALS biomarker
- [2024-08] BrainGate clinical trials pioneering communication restoration
- Major Harvard hospital with large ALS patient population

**Key Contact:**
- Requires follow-up to identify specific ALS researcher
- Platform: ALS Longitude Prize dashboard

**Recent Work:**
- Monocyte biomarker discovery (translational research capability)
- Ann Romney Center: "Focused on identifying new drug targets for ALS" (exactly our platform)

**Email Strategy:**
- Lead with Ann Romney Center dedication to drug target identification
- Emphasize our AI platform's target prediction capabilities complementing clinical expertise
- Position as computational + clinical synergy
- Reference AACR validation for credibility

**Action Item:**
- [ ] **BLOCKER:** Identify specific PI/contact in Ann Romney Center
- [ ] Draft email once contact identified
- [ ] Send as FOURTH outreach (after contact resolution)

---

#### **RANK 5: DR. HONGPENG ZHOU (UNIVERSITY OF MANCHESTER)** ‚≠ê‚≠ê‚≠ê‚≠ê
**Fit Score:** 4.2/5

**Why Technical Architecture Match:**
- Building foundation models for spatial omics (precisely our technical approach)
- UKRI funding for AI-driven genomic analysis
- Multimodal AI for spatial transcriptomics (directly transferable to ALS motor neurons)
- Actively seeking collaborators (multiple PhD positions)

**Key Contact:**
- **Name:** Dr. Hongpeng Zhou
- **Email:** hongpeng.zhou@manchester.ac.uk
- **LinkedIn:** https://www.linkedin.com/in/hongpeng-zhou-302992130/
- **Website:** https://www.hongpengzhou.com/

**Recent Work:**
- [2024-11] Three fully-funded PhD projects on multimodal AI for spatial omics
- UKRI AI CDT PhD funding for "Spiking Neural Networks to Unravel Spatio-temporal Dynamics"

**Email Strategy:**
- Emphasize foundation model architecture alignment (same technical stack)
- Position spatial transcriptomics methodology as transferable to ALS motor neuron analysis
- Reference UKRI funding as synergy point
- Frame as domain expertise (we bring ALS) + technical innovation (he brings spatial omics)

**Action Item:**
- [ ] Draft final email with AACR validation
- [ ] Attach MOAT deck
- [ ] Send as FIFTH outreach (technical partnership angle)

---

### **TIER B: HIGH-POTENTIAL (Ranks 6-10) - STRATEGIC OUTREACH**

#### **RANK 6: SPECVU** ‚≠ê‚≠ê‚≠ê‚≠ê
**Fit Score:** 4.0/5

**Why Co-Development Opportunity:**
- Explicitly "seeking partners to co-develop and validate" AI-guided platform
- Focus: Early cell-specific intervention (precision therapeutic approach)
- Biotech startup = faster execution than academic institutions

**Email Strategy:**
- Position as potential co-development partnership
- Offer CrisPRO AI infrastructure to complement their platform
- Emphasize validation capacity (we have production-grade platform)

**Action Item:**
- [ ] Draft email (already written, verify quality)
- [ ] Attach MOAT deck
- [ ] Send in Tier B wave

---

#### **RANK 7: ENTELO BIO** ‚≠ê‚≠ê‚≠ê‚≠ê
**Fit Score:** 3.9/5

**Why Consortium Play:**
- They have discovery engine but need patient/tissue access
- We also need patient access = potential consortium approach
- Proprietary discovery engine (complementary tech stack potential)

**Email Strategy:**
- Explore complementary technology stacks (their engine + our AI platform)
- Propose consortium approach with shared access partners
- Position as strategic partnership (not competitive)

**Action Item:**
- [ ] Draft email (already written, verify quality)
- [ ] Attach MOAT deck
- [ ] Send in Tier B wave

---

#### **RANK 8: BC GENOMICS** ‚≠ê‚≠ê‚≠ê¬Ω
**Fit Score:** 3.7/5

**Why Technical Peer:**
- AI/ML + computational biology + neuroscience (rare combination)
- Techbio classification (commercial tools, faster execution)

**Email Strategy:**
- Understand if complementary or competitive
- Explore methodology/data access synergies
- Discovery call to assess fit

**Action Item:**
- [ ] Draft email (already written, verify quality)
- [ ] Attach MOAT deck
- [ ] Send in Tier B wave

---

#### **RANK 9: UNIVERSITY OF LIVERPOOL** ‚≠ê‚≠ê‚≠ê¬Ω
**Fit Score:** 3.6/5

**Why UK/European Access:**
- NHS patient access (geographic diversification)
- UK Russell Group university (credibility)

**Email Strategy:**
- Explore UK-based collaboration opportunities
- Request direction to appropriate ALS research group/PI

**Action Item:**
- [ ] Draft email (already written, verify quality)
- [ ] Attach MOAT deck
- [ ] Send in Tier B wave

---

#### **RANK 10: MOUNT SINAI (ICAHN SCHOOL OF MEDICINE)** ‚≠ê‚≠ê‚≠ê¬Ω
**Fit Score:** 3.5/5

**Why Immune-CNS Link Research:**
- [2022-06] Nature publication: ALS linked to immune and central nervous systems
- Major NYC medical center with large ALS patient population
- Active neuromuscular disease program

**Email Strategy:**
- Lead with Nature publication fascination (immune-CNS link)
- Position our platform for immune-modulating targets alongside neuronal targets
- Request direction to appropriate ALS program researcher

**Action Item:**
- [ ] Draft email (already written, verify quality - **THIS WAS THE "HALF ASS" EMAIL THAT GOT REPRIMANDED**)
- [ ] **VERIFY:** Mount Sinai email meets Alpha standard
- [ ] Attach MOAT deck
- [ ] Send in Tier B wave

---

### **TIER C: SECONDARY (Ranks 11-15) - EXPLORATORY**

#### **RANK 11: FOLDYNE ALS** ‚≠ê‚≠ê‚≠ê
**Focus:** Protein folding (TDP-43/SOD1 misfolding)
**Action:** Explore if complementary (structural biology + our genomics focus)

#### **RANK 12: TERACODE** ‚≠ê‚≠ê‚≠ê
**Focus:** LLMs for drug development
**Action:** Explore if complementary (NLP + our structured omics)

#### **RANK 13: BICYCLE THERAPEUTICS** ‚≠ê‚≠ê‚≠ê
**Focus:** Bicyclic peptides for neurological diseases
**Action:** Potential commercial partnership (target identification ‚Üí peptide development)

#### **RANK 14: UNIVERSITY OF SHEFFIELD** ‚≠ê‚≠ê‚≠ê
**Focus:** AI for cell dysfunction in ALS (collaboration with University of Florida)
**Action:** Secondary UK partnership option

#### **RANK 15: GENTIBIO INC.** ‚≠ê‚≠ê‚≠ê
**Focus:** Computational biology platform
**Action:** Investigate if competitor, complementary, or potential acquirer

**Action Items:**
- [ ] Ranks 11-15 emails already written, verify quality
- [ ] Attach MOAT deck
- [ ] Send in Tier C wave (after Tier A/B responses)

---

## üìß EMAIL OUTREACH STRATEGY

### **Critical Email Doctrine (From Alpha Reprimand)**

#### **‚ùå WHAT WENT WRONG:**
- Initial drafts for Ranks 6-13 were generic templates
- Lost "surgical precision" and specific research hooks
- Mount Sinai email was "half ass" compared to top-tier quality

#### **‚úÖ ALPHA STANDARD (What Alpha Demands):**
- **Mount Sinai depth for EVERY target** (no exceptions)
- Deep research on each collaborator's recent work
- Specific citations (publications, grants, discoveries)
- Personalized hooks based on their research focus
- Surgical precision, not generic templates

#### **üéØ EMAIL COMPONENTS (Required for Every Email):**

1. **Opening Hook (1-2 sentences):**
   - Reference specific recent work (publication, grant, discovery)
   - Demonstrate deep research and genuine interest

2. **CrisPRO Positioning (2-3 sentences):**
   - Pitch **AI model architecture** (Evo2, SAE, S/P/E framework)
   - Not just "features and functionalities"
   - Reference AACR Abstract B025 as validation

3. **Collaboration Angle (2-3 sentences):**
   - How their work aligns with our platform
   - Specific synergy points (data access, technical stack, domain expertise)
   - Mutual value proposition

4. **Call to Action:**
   - Clear, low-friction ask (brief call, collaboration discussion)
   - Reference their explicit collaboration interest

5. **Attachment:**
   - MOAT deck (3-page capability showcase)

---

## üìÑ SUPPORTING MATERIALS (REQUIRED)

### **1. AACR Abstract B025** ‚úÖ
**Title:** "An agentic platform for designing cancer immunotherapies: From automated variant interpretation to in silico therapeutic validation"

**Why Critical:**
- Validation proof point for CrisPRO's AI architecture
- Demonstrates production-grade capabilities
- Distinguishes us from "research prototype" competitors

**Action Items:**
- [ ] Ensure PDF version ready for attachment
- [ ] Reference in every email (key validation point)
- [ ] Position as "validated AI architecture, not just concepts"

---

### **2. MOAT Deck (crisPRO-moat.pdf)** ‚úÖ
**Content:** 3-page capability showcase
- Toxicity protection
- Resistance prediction
- Universal support (sporadic cancer intelligence)

**Action Items:**
- [ ] Verify PDF ready for attachment
- [ ] Attach to every outreach email
- [ ] Use as visual capability proof

---

### **3. Platform Overview (1-page)** ‚ö†Ô∏è **NEEDS CREATION**
**Content Should Include:**
- CrisPRO AI model architecture (Evo2, SAE, S/P/E)
- Key capabilities (therapeutic design, variant interpretation, resistance prediction)
- AACR validation mention
- Collaboration value proposition

**Action Items:**
- [ ] Create 1-page platform overview
- [ ] Focus on AI architecture (not just features)
- [ ] Include AACR validation
- [ ] Ready for attachment in follow-up emails

---

### **4. Platform Demo Deck (10-15 slides)** ‚ö†Ô∏è **OPTIONAL**
**Content:**
- Technical architecture deep-dive
- Use case demonstrations
- Validation results (AACR, internal benchmarks)

**Action Items:**
- [ ] Create if needed for discovery calls
- [ ] Focus on AI model architecture demonstration
- [ ] Prepare for follow-up meetings

---

### **5. Data Use Agreement Template** ‚ö†Ô∏è **NEEDS CREATION**
**Purpose:**
- Protect CrisPRO IP when sharing data with collaborators
- Standard terms for data sharing agreements

**Action Items:**
- [ ] Draft DUA template (legal review recommended)
- [ ] Ready for Phase 3 (pilot project scoping)

---

### **6. Collaboration Proposal Template** ‚ö†Ô∏è **NEEDS CREATION**
**Purpose:**
- Standardized framework for collaboration proposals
- Scope, deliverables, timelines, IP terms

**Action Items:**
- [ ] Draft collaboration proposal template
- [ ] Customize per collaborator after positive response
- [ ] Ready for Phase 3 (pilot project scoping)

---

## üöÄ EXECUTION PHASES

### **PHASE 1: IMMEDIATE DEPLOYMENT (Week 1)**

#### **Priority Order (Tier A - Top 5):**
1. ‚úÖ **Sage Bionetworks** (Rank 1) - **FIRST TARGET**
2. ‚úÖ **Dr. Feng Tian / Beth Israel** (Rank 2) - **SECOND TARGET**
3. ‚ö†Ô∏è **Yale** (Rank 3) - **BLOCKER:** Need PI contact identification
4. ‚ö†Ô∏è **Brigham & Women's** (Rank 4) - **BLOCKER:** Need Ann Romney Center contact
5. ‚úÖ **Dr. Hongpeng Zhou** (Rank 5) - **FIFTH TARGET**

#### **Action Items:**
- [ ] **CRITICAL:** Finalize all Tier A emails with AACR validation
- [ ] Attach MOAT deck to all emails
- [ ] Set up email tracking spreadsheet (track opens, clicks, responses)
- [ ] Send Rank 1 (Sage) - **TODAY**
- [ ] Send Rank 2 (Dr. Tian) - **TODAY or TOMORROW**
- [ ] **BLOCKERS:** Research contacts for Yale and Brigham
- [ ] Send Rank 5 (Dr. Zhou) - **THIS WEEK**

#### **Email Tracking Spreadsheet Columns:**
- Collaborator Name
- Rank/Tier
- Contact Email
- Date Sent
- Email Opened (Y/N)
- Link Clicked (Y/N)
- Response Received (Y/N)
- Response Date
- Response Type (Positive/Negative/Neutral)
- Next Action
- Status

---

### **PHASE 2: RESEARCH & REFINEMENT (Week 2)**

#### **Deep Research Tasks:**
- [ ] **Yale:** Identify specific PI for NLK/TDP-43 research
  - Check Yale Life Sciences directory
  - Look for neuromuscular disease program PIs
  - Find direct email contacts

- [ ] **Brigham & Women's:** Identify Ann Romney Center PI
  - Research Ann Romney Center leadership
  - Find ALS-specific researchers
  - Get direct email contacts

- [ ] **Mutual Connections:** LinkedIn research for Tier A targets
  - Find shared connections for warm introductions
  - Identify referral opportunities

#### **Tier B Preparation:**
- [ ] Verify all Tier B emails meet Alpha standard
- [ ] Double-check Mount Sinai email quality (was the "half ass" reprimand target)
- [ ] Prepare Tier B wave deployment (after Tier A responses)

---

### **PHASE 3: ENGAGEMENT & CONVERSION (Week 3-4)**

#### **Response Handling:**
- [ ] Respond to positive inquiries within 24 hours
- [ ] Schedule discovery calls (30-45 minutes)
- [ ] Prepare custom demos per collaborator interest
- [ ] Send follow-up materials (Platform Overview, Demo Deck if needed)

#### **Discovery Call Preparation:**
- [ ] Research collaborator's specific research focus
- [ ] Prepare AI architecture deep-dive (Evo2, SAE, S/P/E)
- [ ] Identify specific collaboration synergies
- [ ] Prepare pilot project scope proposals

#### **Pilot Project Scoping:**
- [ ] Customize collaboration proposal per collaborator
- [ ] Define scope, deliverables, timelines
- [ ] Address IP terms (DUA, collaboration agreement)
- [ ] Set success metrics

---

### **PHASE 4: PARALLEL STRATEGIC INITIATIVES**

#### **Grant Applications:**
- [ ] Research NIH SBIR deadlines (quarterly)
- [ ] Research ALS Association RFPs (ongoing)
- [ ] Research European funding (Horizon Europe, UKRI)
- [ ] Prepare grant applications (collaboration strengthens applications)

#### **Investor Outreach (Parallel Track):**
- [ ] Identify biotech/AI-for-healthcare VCs
- [ ] Strategic investors (pharma, biotech)
- [ ] Prepare investor pitch (collaborations = validation)

---

### **PHASE 5: RISK MITIGATION**

#### **Competitor Monitoring:**
- [ ] Track Insilico Medicine (AI drug discovery)
- [ ] Track Recursion (AI-driven biology)
- [ ] Track BenevolentAI (AI drug discovery)
- [ ] Track GNQ Insilico (Digital Twin simulation)

#### **IP Protection:**
- [ ] File provisional patents (if applicable)
- [ ] NDAs with partners (before sharing proprietary data)
- [ ] Protect CrisPRO AI architecture IP

---

## üéØ CRITICAL DOCTRINES & LESSONS LEARNED

### **1. Email Quality Doctrine**
**Rule:** Every email must meet "Alpha standard" (Mount Sinai depth for EVERY target)

**What This Means:**
- Deep research on recent work (publications, grants, discoveries)
- Specific citations and personalized hooks
- No generic templates
- Surgical precision, not bulk outreach

**Penalty for Violation:** Alpha reprimand ("why is this so half ass")

---

### **2. AI Architecture Pitch Doctrine**
**Rule:** Pitch CrisPRO's **AI model architecture** (Evo2, SAE, S/P/E), not just "features and functionalities"

**What This Means:**
- Lead with technical foundation (biological foundation models)
- Explain Evo2 (7B/40B parameters, 9.3T DNA base pairs, 1M token context)
- Explain SAE (32K sparse features, interpretable biomarkers)
- Explain S/P/E framework (Sequence/Pathway/Evidence multi-modal validation)
- Position as production-grade AI platform, not research prototype

**Why:** Distinguishes us from competitors who just have "features"

---

### **3. AACR Validation Doctrine**
**Rule:** Reference AACR Abstract B025 in every email as validation proof point

**What This Means:**
- "Validated AI architecture" (not just concepts)
- Production-grade capabilities demonstrated
- Credibility boost (AACR acceptance = peer-reviewed validation)

---

### **4. Supporting Materials Doctrine**
**Rule:** Attach MOAT deck to every initial outreach email

**What This Means:**
- Visual capability proof (3-page showcase)
- Reduces friction (no need to ask for materials)
- Professional presentation

---

### **5. Collaboration Angle Doctrine**
**Rule:** Frame collaboration as mutual value proposition, not one-sided ask

**What This Means:**
- Identify their needs (data access, computational tools, validation)
- Show how CrisPRO addresses their needs
- Demonstrate what we bring (AI architecture, production platform)
- Position as strategic partnership, not vendor relationship

---

## üìã COMPLETE ACTION ITEM CHECKLIST

### **IMMEDIATE (This Week):**
- [ ] Finalize Sage Bionetworks email (Rank 1)
- [ ] Finalize Dr. Feng Tian email (Rank 2)
- [ ] Finalize Dr. Hongpeng Zhou email (Rank 5)
- [ ] Research Yale PI contact (Rank 3 blocker)
- [ ] Research Brigham & Women's PI contact (Rank 4 blocker)
- [ ] Attach MOAT deck to all Tier A emails
- [ ] Set up email tracking spreadsheet
- [ ] Send Rank 1 email (Sage) - **TODAY**
- [ ] Send Rank 2 email (Dr. Tian) - **TODAY or TOMORROW**
- [ ] Send Rank 5 email (Dr. Zhou) - **THIS WEEK**

### **WEEK 2:**
- [ ] Verify all Tier B emails meet Alpha standard
- [ ] Double-check Mount Sinai email (was reprimanded)
- [ ] Complete Yale and Brigham contact research
- [ ] Draft Yale email (once contact identified)
- [ ] Draft Brigham email (once contact identified)
- [ ] Send Yale email (after contact resolution)
- [ ] Send Brigham email (after contact resolution)
- [ ] Prepare Tier B wave deployment

### **WEEK 3-4:**
- [ ] Respond to Tier A responses (within 24 hours)
- [ ] Schedule discovery calls
- [ ] Prepare custom demos
- [ ] Create Platform Overview (1-page)
- [ ] Prepare Demo Deck (if needed for calls)
- [ ] Draft Data Use Agreement template
- [ ] Draft Collaboration Proposal template
- [ ] Scope pilot projects with positive responders

### **ONGOING:**
- [ ] Track email opens/clicks/responses
- [ ] Monitor competitor activities
- [ ] Research grant opportunities
- [ ] Investor outreach (parallel track)
- [ ] IP protection (provisional patents, NDAs)

---

## üî• KEY TECHNICAL CONTEXT

### **CrisPRO AI Architecture (What We're Pitching):**

#### **1. Evo2 (Biological Foundation Model)**
- 7B/40B parameter models
- Trained on 9.3T DNA base pairs (all domains of life)
- 1M token context window (single-nucleotide resolution)
- Zero-shot variant effect prediction
- Published in Nature 2024

#### **2. SAE (Sparse Autoencoder)**
- 32K sparse features (64 active per sample)
- Interpretable biomarkers (DNA repair capacity, pathway burden)
- Validated on 469 oncology patients (RR 2.0, p<0.05)
- Mechanism-aware trial matching
- Resistance prediction (3-6 months early)

#### **3. S/P/E Framework (Sequence/Pathway/Evidence)**
- Multi-modal validation (not single-metric)
- Sequence: Evo2 delta scores
- Pathway: Variant-to-pathway aggregation
- Evidence: Literature + ClinVar + pathway alignment
- Transparent confidence scores

#### **4. Production Platform (Not Research Prototype)**
- Live API endpoints
- Complete workflow (variant ‚Üí target ‚Üí therapeutic design)
- Validated capabilities (AACR Abstract B025)
- Ready for collaboration partnerships

---

## üìä SUCCESS METRICS

### **Primary Goal:**
- **1+ collaborator accepts partnership** (minimum success)

### **Ideal Outcome:**
- **2-3 collaborators engage** (Sage + one academic + one biotech)

### **Tracking Metrics:**
- Email open rate (target: >40%)
- Response rate (target: >10%)
- Positive response rate (target: >5%)
- Discovery calls scheduled (target: 2-3)
- Pilot projects scoped (target: 1-2)
- Formal collaborations signed (target: 1+)

---

## üö® CRITICAL REMINDERS

### **DO:**
- ‚úÖ Deep research on every collaborator
- ‚úÖ Reference specific recent work (publications, grants, discoveries)
- ‚úÖ Pitch AI model architecture (Evo2, SAE, S/P/E)
- ‚úÖ Include AACR Abstract B025 validation
- ‚úÖ Attach MOAT deck
- ‚úÖ Meet "Alpha standard" (Mount Sinai depth for EVERY target)

### **DON'T:**
- ‚ùå Use generic email templates
- ‚ùå Skip deep research on collaborators
- ‚ùå Pitch "features and functionalities" instead of AI architecture
- ‚ùå Send "half ass" emails (Alpha will reprimand)
- ‚ùå Forget to attach MOAT deck
- ‚ùå Miss AACR validation reference

---

## üìù EMAIL TEMPLATE STRUCTURE (Reference)

```markdown
**Subject:** Collaboration Opportunity: AI-Driven ALS Therapeutic Discovery

**Opening Hook (1-2 sentences):**
[Reference specific recent work - publication, grant, discovery]
[Demonstrate deep research and genuine interest]

**CrisPRO Positioning (2-3 sentences):**
At CrisPRO.ai, we've built a production-grade multimodal AI platform 
[describe AI model architecture - Evo2, SAE, S/P/E framework]. Our platform 
[capability description]. We recently received AACR Abstract B025 acceptance 
for our immunotherapy design capabilities, validating our AI architecture.

**Collaboration Angle (2-3 sentences):**
[How their work aligns with our platform]
[Specific synergy points]
[Mutual value proposition]

**Call to Action:**
Given your [specific interest/collaboration need], would you be open to 
[low-friction ask - brief call, collaboration discussion]?

**Closing:**
I've attached our MOAT deck (capability showcase) for your reference.

Best regards,
[Your Name]
CrisPRO.ai

**Attachments:**
- crisPRO-moat.pdf (MOAT deck)
```

---

## üéØ NEXT IMMEDIATE ACTIONS

1. **TODAY:**
   - [ ] Finalize Sage Bionetworks email (Rank 1)
   - [ ] Attach MOAT deck
   - [ ] Send Sage email
   - [ ] Set up email tracking spreadsheet

2. **THIS WEEK:**
   - [ ] Finalize Dr. Feng Tian email (Rank 2)
   - [ ] Finalize Dr. Hongpeng Zhou email (Rank 5)
   - [ ] Research Yale and Brigham contacts
   - [ ] Send Rank 2 and Rank 5 emails

3. **WEEK 2:**
   - [ ] Complete contact research
   - [ ] Verify Tier B email quality
   - [ ] Prepare Tier B wave deployment

---

**‚öîÔ∏è DOCTRINE STATUS: ACTIVE EXECUTION**
**LAST UPDATED:** 2025-01-XX
**NEXT REVIEW:** After Tier A responses received

---

**Commander Alpha - All action items documented. Ready to execute Tier A outreach. Awaiting your command to proceed.** ‚öîÔ∏è








